REGENXBIO appoints Jennifer Zachary to board; annual meeting results ratified

REGENXBIO Inc.

Jennifer Zachary elected Class I director and Audit Committee member, effective June 3, 2022.
Ms. Zachary receives initial equity award of $550,000 (75% option, 25% RSUs) at $22.84 exercise price.
Annual meeting re-elected Allan Fox and Alexandra Glucksmann as Class I directors; PwC ratified as auditor.
Advisory vote on named executive officer compensation approved with 96% of votes cast in favor.
Ms. Zachary is EVP & General Counsel of Merck, bringing 20+ years of pharma and regulatory experience.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Zachary

Class I Director

RGNX · REGENXBIO Inc.

Effective: 2022-06-03
Filed: June 7, 2022, 7:59 PM ET

elected Jennifer Zachary as a Class I director of the Company and a member of the Audit Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Zachary was elected as Class I Director at REGENXBIO Inc..

Action: elected
Role: Class I Director

Exact text from the filing

elected Jennifer Zachary as a Class I director of the Company and a member of the Audit Committee, effective immediately.

View on SEC.gov

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-168821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.